6.1 All obligations regarding the date and scope of the project agreed between the client and the Aberdeen Drilling Consultant client must be confirmed in writing. These agreements are concluded in good faith and are carried out with the best efforts, but necessarily taken in advance to know the extent of the difficulties that may relate to performance in certain areas. For this reason, Aberdeen Drilling Consultants says it is prepared to do its best to meet these obligations to clients regarding the timing and extent of the work, but Aberdeen Drilling Consultants cannot guarantee performance on these two points (see Article 13). Genmab is a publicly traded international biotechnology company specializing in the production and development of differentiated antibody therapy drugs for the treatment of cancer. The company founded in 1999 is the creator of the following authorized antibodies: DARZALEX® (daratumumab, in the contract with Janssen Biotech, Inc.) for the treatment of certain indications of multiple myeloma in areas such as the United States, Europe and Japan, kesimpta® (subcutaneous atumumab, in agreement with Novartis AG), for the treatment of adults with helical multiple sclerosis in the United States and TEPEZZA® (teprotumabababababumab , as part of an agreement with Roche). ( – Horizon Therapeutics plc) which issues a sublicensing for the treatment of thyroid diseases in the United States. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in the United States and Europe, has been approved in the United States and Europe for the treatment of adult patients with certain indications of multiple myeloma. The first approved vonmab dernotherapy, Arzerra® (ofatumumab, in agreement with Novartis AG), approved for the treatment of certain chronic indications of lymphocytic leukemia, is available in Japan and is also available in other areas via compassionate use or oncology programs. Daratumumab is in clinical development for the treatment of other indications of multiple myeloma, other blood cancers and amylosis. Genmab also has a large pipeline of clinical and preclinical products. Genmab`s technology base consists of validated and proprietary next-generation antibody technologies – the duobody platform® for the production of bi-specific antibodies, the HexaBody platform® which produces strengthened antibodies, the HexElect platform®, which combines two co-dependent hexabody molecules to introduce selective active ingredients while maximizing therapeutic power, and the DuoHexaBody® platform that enhances the potential power of bi-specifics.
The company intends to use these technologies to create opportunities for all or co-ownership of future products. Genmab maintains alliances with leading pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark, with locations in Utrecht, the Netherlands, Princeton, New Jersey, USA.